2010 Competition Prescription 
European Pharmaceutical Review
JULY 4, 2024
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. The MA pathway is applicable for herbal medicines designed to treat more serious health conditions and require a medical prescription or the supervision of a medical practitioner. 2012/1916).
PM360
FEBRUARY 1, 2024
The landscape is highly competitive with new prescription medications launching worldwide each year. Early shaping of the label during clinical trial design, risk mitigation, and avoiding approval delays are crucial for seizing a competitive advantage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 6, 2023
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.
Pharmaceutical Technology
DECEMBER 4, 2022
Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Although AbbVie will now face competition from these products, it has built a strong market for Humira, says Hlávka, adding that it will likely continue reporting significant revenues.
Pharmaceutical Technology
OCTOBER 25, 2022
Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. Of those 131 approved FDCs, 98 were oral dosage forms.
Pharmaceutical Technology
MAY 29, 2008
PT: How do you think GSK is placed competitively? Important elements within this expectation are the build up of strong contributions from Rotarix, Cervarix and Tykerb, while the outlook for GSK’s important asthma franchise becomes less clear beyond 2010. PD: We believe that GSK has the strongest pipeline in the industry.
pharmaphorum
JANUARY 27, 2023
Demand has also increased due to changes in prescribing protocols, leading to a higher underlying number of prescriptions for certain antibiotic medicines. He previously held regional leadership roles at Sandoz between 2005 and 2010. The impact is two-fold.
Expert insights. Personalized for you.
103 
Let's personalize your content